A novel approach for establishing cardiovascular drug efficacy

Nature Reviews Drug Discovery

Volumn 13, Issue 12, 2014, Pages 942-

  Heerspink, Hiddo J Lambers ^a   Grobbee, Diederick E ^b   De Zeeuw, Dick ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; KIDNEY DISEASE; LETTER; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RENAL PROTECTION; RISK ASSESSMENT; RISK REDUCTION; SCORING SYSTEM; TREATMENT RESPONSE; ANIMAL; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; TREATMENT OUTCOME; TRENDS;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; TREATMENT OUTCOME;

EID: 84927176250     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4090-c2     Document Type: Letter

References (16)

1. Arrowsmith, J. & Miller, P. Phase II and Phase III attrition rates 2011-2012. Nature Rev. Drug Discov. 12, 569 (2013).
2. Prentice, R. L. Surrogate endpoints in clinical trials: definition and operational criteria. Stat. Med. 8, 431-440 (1989).
3. Eijkelkamp, W. B. et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J. Am. Soc. Nephrol. 18, 1540-1546 (2007).
4. Jafar, T. H. et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int. 60, 1131-1140 (2001).
5. de Zeeuw, D. et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110, 921-927 (2004).
6. Albert, M. A., Danielson, E., Rifai, N. & Ridker, P. M. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286, 64-70 (2001).
7. Savarese, G. et al. Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis. Int. J. Cardiol. 167, 2482-2489 (2013).
8. Ridker, P. M. et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373, 1175-1182 (2009).
9. De Jager, J. et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J. Intern. Med. 257, 100-109 (2005).
10. Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A. & List, J. F. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375, 2223-2233 (2010).
11. Nauck, M. A. et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 34, 2015-2022 (2011).
12. Miao, Y. et al. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia 54, 44-50 (2011).
13. Hou, F. F. et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J. Am. Soc. Nephrol. 18, 1889-1898 (2007).
14. Lambers Heerspink, H. J. et al. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial. Eur. J. Prev. Cardiol. 21, 299-309 (2014).
15. Smink, P. A. et al. The importance of short-term off-target effects in estimating the long-term renal and cardiovascular protection of angiotensin receptor blockers. Clin. Pharmacol. Ther. 95, 208-215 (2014).
16. Smink, P. A. et al. A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers. Eur. J. Preventive Cardiol. 21, 434-441 (2014).